Chronic Hepatitis C Therapy
Mostrando 1-12 de 120 artigos, teses e dissertações.
-
1. Treatment of Hepatitis C with Direct-Acting Antivirals does not Induce Significant Arrhythmias
Abstract Background Chronic Hepatitis C (CHC) therapy with direct-acting antivirals (DAAs) has high efficacy and safety, but some cases of bradyarrhythmias have been described. Objective To evaluate heart rhythm disorders during DAA treatments. Methods Forty-eight patients with CHC (mean 61 years of age; 56% males; 73% HCV genotype 1) were evaluated be
International Journal of Cardiovascular Sciences. Publicado em: 2022
-
2. Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
ABSTRACT Background: To analyze the effectiveness and the safety of Sofosbuvir-based regimens to treat patients with chronic hepatitis C virus (HCV) infection and chronic kidney disease (CKD). Methods: A retrospective, observational study in patients with chronic HCV infection and CKD treated with Sofosbuvir-based regimens was performed. Liver fibrosis, co
Braz J Infect Dis. Publicado em: 2020-02
-
3. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY
RESUMO CONTEXTO: O manejo e a possibilidade de erradicação da infecção pelo vírus da hepatite C têm sido muito pesquisados nos últimos anos pela importância que representam na saúde pública para a população mundial. A obtenção de dados que auxiliem o enfrentamento dessa patologia resulta na melhor qualidade de vida dos seus portadores. O pres
Arq. Gastroenterol.. Publicado em: 28/11/2019
-
4. Case for diagnosis. Sclerodermiform manifestations of porphyria cutanea tarda secondary to hepatitis C
Abstract: A 63-year-old black female patient with blisters and exulcerations on the face, neck, upper limbs, and subsequent evolution with hypochromic sclerotic areas and alopecia, is reported. Chronic hepatitis C and presence of high levels of porphyrins in urine were demonstrated. There was complete remission with the use of hydroxychloroquine, photoprotec
An. Bras. Dermatol.. Publicado em: 17/10/2019
-
5. Hepatitis B virus infection among oncohematologic disease patients in Central Brazil: prevalence, risk factors and immunization
ABSTRACT Introduction: Carriers of oncohematological diseases are at high risk for hepatitis B virus (HBV) infection. Objective and method: To investigate the epidemiology of HBV infection in Goiânia, Central Brazil, 322 individuals with oncohematological diseases (leukemias, Hodgkin lymphoma and non-Hodgkin lymphoma) were interviewed and blood samples we
Hematol., Transfus. Cell Ther.. Publicado em: 10/10/2019
-
6. Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies
ABSTRACT Due to the severity of chronic hepatitis C, there are multiple factors that can negatively affect the quality of life of infected patients. The aim of this study was to evaluate changes in the health-related quality of life (HRQoL) in patients under second-generation direct-acting antiviral (DAA) (interferon-free) therapies and to assess treatment e
Rev. Inst. Med. trop. S. Paulo. Publicado em: 14/11/2018
-
7. Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
ABSTRACT In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were discontinued in 2015. The short period of use in thera
Rev. Inst. Med. trop. S. Paulo. Publicado em: 28/06/2018
-
8. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness
Rev. Soc. Bras. Med. Trop.. Publicado em: 2018-04
-
9. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus
ABSTRACT Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC
Rev. Inst. Med. trop. S. Paulo. Publicado em: 06/11/2017
-
10. Prevalence of Hepatitis B and C virus infection among alcoholic individuals: importance of screening and vaccination
ABSTRACT Drug users have been reported to have an increased risk for acquisition of viral hepatitis. This study aims to evaluate the prevalence of HBV and HCV infection and usefulness of saliva for HBsAg and anti-HCV detection in alcoholic patients.A total of 90 alcoholic patients were recruited in 2013. HBsAg and anti-HCV were tested in serum and saliva, an
Rev. Inst. Med. trop. S. Paulo. Publicado em: 03/08/2017
-
11. Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil
Abstract INTRODUCTION: HIV and viral hepatitis infections are major causes of chronic disease worldwide and have some similarities with regard to routes of transmission, epidemiology, front barriers faced during access of treatment, and strategies for a global public health response. The objective was to describe the HIV-1 subtypes, viral tropism and single
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-08
-
12. Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation
Recurrent hepatitis C after orthotopic liver transplantation (OLT) is universal and can lead to graft failure and, consequently, reduced survival. Hepatitis C treatment can be used to prevent these detrimental outcomes. The aim of this study was to describe rates of hepatitis C recurrence and sustained virological response (SVR) to interferon-based treatment
Braz J Med Biol Res. Publicado em: 09/01/2017